drugset
drugset / Trial / NCT05170685

Expanded Access for Fixed-Dose Combination of Nivolumab Plus Relatlimab

NCT05170685 ↗

Expanded access No longer available Bristol-Myers Squibb

Summary

This is an expanded access designed to provide access to fixed-dose combination of nivolumab plus relatlimab for eligible participants.

Timeline

Start
—
Primary completion
—
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Background Nivolumab Monoclonal antibody — —
Background Relatlimab Monoclonal antibody — —

Indications

No indication recorded.